Remoxipride, a specific D2 dopamine antagonist: an examination of its self-administration liability and its effects on d-amphetamine self-administration.
The self-administration liability of remoxipride, a specific dopamine D2 antagonist, by laboratory rats was evaluated using an intravenous self-administration paradigm. It was observed that remoxipride failed to support self-administration behavior across the three doses tested. In addition, remoxipride pretreatment attenuated d-amphetamine self-administration. The findings of the present study provide support for the notion that remoxipride appears to have functional similarity in self-administration paradigms as other D2 antagonists.
Department of Psychology, Concordia University, Montreal, Quebec, Canada.
Z
Z
Amit
B R
BR
Smith
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects; D003913:Dextroamphetamine / Q000494:pharmacology*; D018492:Dopamine Antagonists; D008297:Male; D051381:Rats; D017448:Receptors, Dopamine D2; D017330:Remoxipride; D012646:Self Administration
D014150:Antipsychotic Agents; D001549:Benzamides; D018492:Dopamine Antagonists; D017448:Receptors, Dopamine D2; D017330:Remoxipride; D003913:Dextroamphetamine